Your cart is empty.
Männedorf, Switzerland – March 10, 2011 - The Board of Directors of the Tecan Group (SIX Swiss Exchange: TECN) will propose the removal of the registration- and voting limitations to the Annual General Meeting on April 19, 2011. Tecan gives great importance to good corporate governance and takes into account the current requirements of the capital market. The Board of Directors of Tecan believes that the restrictions on registration and voting rights to 5% of share capital as defined in the Articles of Incorporation is no longer appropriate. It will therefore propose at the Annual General Meeting that the restrictions on registration and voting rights be cancelled and Articles 5 and 12 of the Articles of Incorporation be amended accordingly. This will enable Tecan to reinforce shareholders’ participation rights, thereby making the Tecan share more attractive, particularly also in an international environment and with institutional investors.
The details of the proposed amendment to the Articles of Incorporation are presented in the notice of the Annual General Meeting, which will be sent to shareholders and published on the website www.tecan.com at the end of March 2011.
Election of members of the Board of Directors
The Board of Directors will propose the election of two new members, Dr. Oliver S. Fetzer and Erik Walldén, to the Annual General Meeting. The Board will also propose the reelection of current members Rolf A. Classon, Heinrich Fischer, Dr. Lukas Braunschweiler, Dominique F. Baly and Gérard Vaillant. Subject to his reelection, Rolf A. Classon will remain chairman of the Board of Directors.
Board members Prof. Dr. Peter Ryser and Dr. Jürg Meier will not seek reelection at this year’s Annual General Meeting. Chairman Rolf A. Classon would like to thank Peter Ryser and Jürg Meier on behalf of the entire Board of Directors for their commitment and valuable contributions to the strategic development of Tecan.
Proposal of two new members
Oliver S. Fetzer, born in Germany in 1964, has been President and CEO and a member of the Board of Directors of Cerulean Pharma, Inc. in Cambridge, MA (USA), a leading company in the development of nanopharmaceuticals, since 2009. He previously led research and development as well as corporate development at the NASDAQ-listed company Cubist Pharmaceuticals. Between 1992 and 2002, Dr. Fetzer, who has a PhD in pharmaceutical sciences and an MBA, worked for The Boston Consulting Group in the US, Germany and New Zealand; between 2000 and 2002 as Managing Director and Partner. He is a Board member of Auxilium Pharmaceuticals since 2005. Oliver Fetzer is a US citizen.
Erik Walldén, born in 1949, has been CEO of Gyros AB, which is headquartered in Uppsala, Sweden, since 2009. Gyros specializes in utilizing microfluidic technologies and supplies instruments and solutions in the field of microfluids to the biopharmaceutical industry. He has extensive experience in commercializing breakthrough technologies and has held various executive management positions at international biotech companies in Sweden, the US and Switzerland, where he was also responsible for major transactions and the realignment of parts of companies. Between 2004 and 2006, he was President and CEO of Biacore International AB. Mr. Walldén is a member of a number of supervisory and advisory boards. He is a Swedish citizen with studies in analytical chemistry at the University of Uppsala.
Unchanged dividend payout
The Board of Directors will propose an unchanged dividend of CHF 1.00 per share to the shareholders at the Company’s Annual General Meeting on April 19, 2011. The dividend will be paid out from the available reserve for additional paid-in capital and is therefore not subject to withholding tax.
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics. The company specializes in the development, production and distribution of instruments and automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer, Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/ ISIN CH0012100191).
For further information
Head of Corporate Communications & Investor Relations
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89